Alatrofloxacin
Appearance
This article needs additional citations for verification. (August 2014) |
Clinical data | |
---|---|
AHFS/Drugs.com | Micromedex Detailed Consumer Information |
MedlinePlus | a605016 |
Routes of administration | Intravenous |
ATC code |
|
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | N/A |
Protein binding | 76% (trovafloxacin) |
Metabolism | Quickly hydrolyzed to trovafloxacin |
Elimination half-life | 9 to 12 hours (trovafloxacin) |
Excretion | Fecal and renal (trovafloxacin) |
Identifiers | |
| |
CAS Number | |
ChemSpider | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C26H25F3N6O5 |
Molar mass | 558.509 g/mol g·mol−1 |
3D model (JSmol) | |
| |
| |
|
Alatrofloxacin is a bioactive molecule of 4-pyridone group that inhibits bacterial type IIA topoisomerase (DNA gyrase and topoisomerase IV).[1] Alatrofloxacin (Trovan IV) is a fluoroquinolone antibiotic developed by Pfizer, delivered as a mesylate salt.[2]
Trovafloxacin and alatrofloxacin were both withdrawn from the U.S. market in June of 2006.
See also
References
- ^ Forouzesh, Abed; Samadi Foroushani, Sadegh; Forouzesh, Fatemeh; Zand, Eskandar (2019). "Reliable target prediction of bioactive molecules based on chemical similarity without employing statistical methods". Frontiers in Pharmacology. 10: 835. doi:10.3389/fphar.2019.00835. PMC 6676798. PMID 31404334.
{{cite journal}}
: CS1 maint: unflagged free DOI (link) - ^ "Center for Drug Evaluation and Research – Application Number: 020759/020760 – Chemistry Review(s)" (PDF). Food and Drug Administration. Retrieved 29 August 2014.